NeuroXess Launches Pivotal GCP-Compliant Clinical Trial for Its Fully Implantable, Wireless, and Functional ("Triple-Full") Brain-Computer Interface System

Gelonghui, July 7 | According to Jiemian, the “Implantable Brain-Computer Interface System for Compensatory Hand Motor Function,” also known as the “Fully Implantable, Fully Wireless, Fully Functional (‘Three-Full’) Brain-Computer Interface System,” independently developed by NeuroXess, has officially launched its Good Clinical Practice (GCP) registration clinical trial at Huashan Hospital Affiliated to Fudan University. This GCP registration clinical trial adopts a multi-center collaborative model, jointly conducted with a total of 15 Grade A tertiary hospitals in Shanghai and other regions, to evaluate the safety and efficacy of the system in providing upper-limb functional compensation for patients with quadriplegia caused by cervical spinal cord injury. Reportedly, this is the first subdural cortical surface implantable brain-computer interface product to enter the national Class III medical device registration clinical phase, marking a critical step forward in China’s transition of brain-computer interface technology from scientific exploration to large-scale clinical application.